FairJourney Bio Forges End-to-End Antibody Engine with AbTherx Tech

SAN DIEGO, CA – June 23, 2026 – The world of antibody discovery is a complex relay race, where the baton—a promising therapeutic program—is passed between multiple specialist teams, each handoff introducing risk, delay, and cost. FairJourney Bio, a global antibody discovery expert, just announced a move to turn that relay into a solo sprint. Through a strategic partnership with AbTherx, Inc., FJBio is integrating a premier transgenic mouse platform directly into its workflow, creating a seamless, 'one-roof' solution designed to accelerate the journey from immunization to a fully developable drug candidate.

This isn't just an incremental improvement; it's a fundamental re-architecting of the discovery process. For biotech and pharmaceutical partners, it promises an end to the logistical headaches of managing multiple vendors and the scientific jeopardy of a great molecule getting lost in translation between discovery and development. By bringing AbTherx’s validated Atlas™ mouse technology in-house, FairJourney Bio is making a bold statement: the most efficient path to a successful biologic is a straight line.

The 'One-Roof' Philosophy: Redefining Discovery Efficiency

The core of this partnership is the elimination of fragmentation. Traditionally, a company might contract one group for mouse immunization, another for B-cell screening, a third for lead optimization, and yet another for developability and cell-line development. Each transition is a potential point of failure. Data can be misinterpreted, timelines can stretch, and critical nuances of a molecule's behavior can be overlooked.

FairJourney Bio’s CEO, Dr. Werner Lanthaler, articulated the vision behind the move. “We are investing so a partner’s programme can run from immunisation to a developability-assessed lead inside FJBio, without changing hands,” he commented. “Following a molecule under 'one roof' and with one team of scientists increases probabilities of success significantly.”

This integrated model directly addresses a major pain point in a biologics contract research (CRO) market that, while booming, remains highly siloed. With the market valued at $36 billion this year and projected to soar to $126 billion by 2035, the demand for outsourced expertise is clear. However, efficiency gains have been elusive. FJBio's strategy is to capture a larger share of this growth not by being just another service provider, but by being an integrated engine. This approach allows a single, cohesive team to shepherd a program across FJBio’s global sites in Porto, Cambridge, and San Diego, ensuring continuity of knowledge and strategy from day one.

Under the Hood: The Atlas™ Engine and B-Cell Navigator

For this integrated model to work, the foundational technology must be best-in-class. This is where AbTherx’s Atlas™ Mice come in. The platform is not an unknown quantity; it was built by the veteran team behind the legendary HuMAb Mouse®, a technology that has already contributed to thirteen marketed antibody therapeutics. This legacy provides a powerful baseline of trust and proven success.

AbTherx’s platform includes two key technologies now available to FJBio partners:

• Atlas™ Full Human Diversity (FHD) Mice: These mice are engineered to produce a vast, human-like antibody response. By incorporating VH and VK gene alleles that represent over 99% of the expressed human repertoire, they generate a rich pool of diverse, fully human antibody candidates. This breadth at the source is critical for finding rare antibodies with ideal properties against challenging targets.

• Atlas™ Common Light Chain (cLC) Mice: As therapeutic formats grow more complex, particularly with bi- and multi-specific antibodies, manufacturability becomes a major hurdle. The cLC mice solve this by producing antibodies with a fixed light chain, vastly simplifying the downstream engineering and production of these sophisticated molecules, ensuring they are built to be manufacturable from the start.

“The AbTherx team has spent decades building, refining, and implementing the premier technologies for human antibody discovery,” said Dan Rohrer, Chief Technology Officer at AbTherx. “Uniting our proprietary Full Human Diversity and Common Light Chain technologies with FairJourney Bio’s exceptional, quality-driven scientific team creates a powerful synergy.”

This synergy is most evident where the Atlas™ platform feeds directly into FJBio’s B-Cell Navigator, its proprietary single B-cell screening and developability engine. This crucial step ensures that the vast diversity generated by the Atlas mice isn't just a numbers game. Instead, it’s about intelligently filtering for hits that are not only potent binders but are also stable, manufacturable, and non-immunogenic—a concept known as 'developability by design'. Instead of finding a promising but flawed candidate that needs to be fixed later, the goal is to identify a superior, development-ready molecule from the very beginning.

A Strategic Play in a Competitive Field

This partnership is a calculated move in the fiercely competitive antibody discovery landscape. It signals a clear strategic direction under the leadership of Dr. Lanthaler, who, during his 15-year tenure as CEO of Evotec, demonstrated a mastery of building technology-driven, integrated platforms. His vision of leveraging “shared data- and AI-driven innovation platforms” to cut costs and timelines is now being implemented at FJBio.

This isn't an isolated investment. It follows FJBio’s recent launch of a state-of-the-art Cryo-EM facility in San Diego, which integrates atomic-resolution structural biology into the discovery workflow. Together, these moves paint a picture of a company aggressively assembling all the necessary components to become a dominant force in biologics discovery. The company is building a comprehensive toolkit that combines best-in-class in vivo platforms, high-throughput screening, deep structural insights, and expert scientific oversight.

By offering the highly sought-after Atlas™ platform as part of an integrated service, FJBio not only enhances its value proposition to existing clients but also creates a compelling draw for new partners who want access to elite technology without the complexities of direct licensing. It's a strategy that differentiates FJBio from both smaller, specialized CROs and other large players who may not offer this level of seamless integration.

From Lab Bench to Patient: The Ultimate Impact

The ultimate goal of any discovery engine is to produce effective medicines. The high attrition rate in drug development, where promising early candidates fail in expensive late-stage trials, is the industry's biggest challenge. Many of these failures can be traced back to poor developability characteristics that were not identified or addressed early enough.

The FJBio-AbTherx partnership tackles this problem at its root. By combining a platform proven to generate superior antibody diversity with a workflow that embeds developability assessment at the earliest possible stage, they aim to de-risk programs and improve the odds of success. The validation is already beginning to emerge; the first therapeutic derived from the Atlas™ Mouse platform entered Phase 1 clinical trials in the first quarter of 2026, a testament to the technology's ability to deliver clinical-grade candidates efficiently.

For pharmaceutical and biotech innovators, this collaboration offers a clearer, faster, and more secure path forward. By consolidating the most challenging phase of drug discovery under one expert roof, FairJourney Bio is not just offering a service; it's offering a strategic advantage in the race to bring transformative antibody therapeutics to patients.